This interview examines treatment-related cardiotoxicity and the risk of second malignancy in patients with Hodgkin lymphoma.
Treatment-related cardiotoxicity and the risk of second malignancy in survivors of Hodgkin lymphoma who received radiation therapy or chemotherapy is an important consideration given the high cure rate for this disease.
In this interview, Flora van Leeuwen, PhD, of the Netherlands Cancer Institute, discusses strategies to reduce the risk of these late toxicities and highlights some of the key points from an education session she presented at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.
Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
November 3rd 2022Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.